Epigenetics and genetics in endometrial cancer

New carcinogenic mechanisms and relationship with clinical practice

Kouji Banno, Iori Kisu, Megumi Yanokura, Kenta Masuda, Arisa Ueki, Yusuke Kobayashi, Nobuyuki Susumu, Daisuke Aoki

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Endometrial cancer is the seventh most common cancer worldwide among females. An increased incidence and a younger age of patients are also predicted to occur, and therefore elucidation of the pathological mechanisms is important. However, several aspects of the mechanism of carcinogenesis in the endometrium remain unclear. Associations with genetic mutations of cancer-related genes have been shown, but these do not provide a complete explanation. Therefore, epigenetic mechanisms have been examined. Silencing of genes by DNA hypermethylation, hereditary epimutation of DNA mismatch repair genes and regulation of gene expression by miRNAs may underlie carcinogenesis in endometrial cancer. New therapies include targeting epigenetic changes using histone deacetylase inhibitors. Some cases of endometrial cancer may also be hereditary. Thus, patients with Lynch syndrome which is a hereditary disease, have a higher risk for developing endometrial cancer than the general population. Identification of such disease-related genes may contribute to early detection and prevention of endometrial cancer.

Original languageEnglish
Pages (from-to)147-162
Number of pages16
JournalEpigenomics
Volume4
Issue number2
DOIs
Publication statusPublished - 2012 Apr

Fingerprint

Endometrial Neoplasms
Epigenomics
Carcinogenesis
Hereditary Nonpolyposis Colorectal Neoplasms
Inborn Genetic Diseases
Histone Deacetylase Inhibitors
DNA Mismatch Repair
Neoplasm Genes
Gene Expression Regulation
Gene Silencing
Endometrium
MicroRNAs
Genes
Mutation
DNA
Incidence
Population
Neoplasms
Therapeutics

Keywords

  • DNA hypermethylation
  • DNA mismatch repair
  • endometrial cancer
  • epimutation
  • HDAC inhibitor
  • hMLH1
  • lower uterine segment
  • Lynch syndrome
  • miRNA
  • MMR

ASJC Scopus subject areas

  • Genetics
  • Cancer Research

Cite this

Epigenetics and genetics in endometrial cancer : New carcinogenic mechanisms and relationship with clinical practice. / Banno, Kouji; Kisu, Iori; Yanokura, Megumi; Masuda, Kenta; Ueki, Arisa; Kobayashi, Yusuke; Susumu, Nobuyuki; Aoki, Daisuke.

In: Epigenomics, Vol. 4, No. 2, 04.2012, p. 147-162.

Research output: Contribution to journalArticle

Banno, Kouji ; Kisu, Iori ; Yanokura, Megumi ; Masuda, Kenta ; Ueki, Arisa ; Kobayashi, Yusuke ; Susumu, Nobuyuki ; Aoki, Daisuke. / Epigenetics and genetics in endometrial cancer : New carcinogenic mechanisms and relationship with clinical practice. In: Epigenomics. 2012 ; Vol. 4, No. 2. pp. 147-162.
@article{3c42cbb79ac34410ad9c5c7c71b10e55,
title = "Epigenetics and genetics in endometrial cancer: New carcinogenic mechanisms and relationship with clinical practice",
abstract = "Endometrial cancer is the seventh most common cancer worldwide among females. An increased incidence and a younger age of patients are also predicted to occur, and therefore elucidation of the pathological mechanisms is important. However, several aspects of the mechanism of carcinogenesis in the endometrium remain unclear. Associations with genetic mutations of cancer-related genes have been shown, but these do not provide a complete explanation. Therefore, epigenetic mechanisms have been examined. Silencing of genes by DNA hypermethylation, hereditary epimutation of DNA mismatch repair genes and regulation of gene expression by miRNAs may underlie carcinogenesis in endometrial cancer. New therapies include targeting epigenetic changes using histone deacetylase inhibitors. Some cases of endometrial cancer may also be hereditary. Thus, patients with Lynch syndrome which is a hereditary disease, have a higher risk for developing endometrial cancer than the general population. Identification of such disease-related genes may contribute to early detection and prevention of endometrial cancer.",
keywords = "DNA hypermethylation, DNA mismatch repair, endometrial cancer, epimutation, HDAC inhibitor, hMLH1, lower uterine segment, Lynch syndrome, miRNA, MMR",
author = "Kouji Banno and Iori Kisu and Megumi Yanokura and Kenta Masuda and Arisa Ueki and Yusuke Kobayashi and Nobuyuki Susumu and Daisuke Aoki",
year = "2012",
month = "4",
doi = "10.2217/epi.12.13",
language = "English",
volume = "4",
pages = "147--162",
journal = "Epigenomics",
issn = "1750-1911",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Epigenetics and genetics in endometrial cancer

T2 - New carcinogenic mechanisms and relationship with clinical practice

AU - Banno, Kouji

AU - Kisu, Iori

AU - Yanokura, Megumi

AU - Masuda, Kenta

AU - Ueki, Arisa

AU - Kobayashi, Yusuke

AU - Susumu, Nobuyuki

AU - Aoki, Daisuke

PY - 2012/4

Y1 - 2012/4

N2 - Endometrial cancer is the seventh most common cancer worldwide among females. An increased incidence and a younger age of patients are also predicted to occur, and therefore elucidation of the pathological mechanisms is important. However, several aspects of the mechanism of carcinogenesis in the endometrium remain unclear. Associations with genetic mutations of cancer-related genes have been shown, but these do not provide a complete explanation. Therefore, epigenetic mechanisms have been examined. Silencing of genes by DNA hypermethylation, hereditary epimutation of DNA mismatch repair genes and regulation of gene expression by miRNAs may underlie carcinogenesis in endometrial cancer. New therapies include targeting epigenetic changes using histone deacetylase inhibitors. Some cases of endometrial cancer may also be hereditary. Thus, patients with Lynch syndrome which is a hereditary disease, have a higher risk for developing endometrial cancer than the general population. Identification of such disease-related genes may contribute to early detection and prevention of endometrial cancer.

AB - Endometrial cancer is the seventh most common cancer worldwide among females. An increased incidence and a younger age of patients are also predicted to occur, and therefore elucidation of the pathological mechanisms is important. However, several aspects of the mechanism of carcinogenesis in the endometrium remain unclear. Associations with genetic mutations of cancer-related genes have been shown, but these do not provide a complete explanation. Therefore, epigenetic mechanisms have been examined. Silencing of genes by DNA hypermethylation, hereditary epimutation of DNA mismatch repair genes and regulation of gene expression by miRNAs may underlie carcinogenesis in endometrial cancer. New therapies include targeting epigenetic changes using histone deacetylase inhibitors. Some cases of endometrial cancer may also be hereditary. Thus, patients with Lynch syndrome which is a hereditary disease, have a higher risk for developing endometrial cancer than the general population. Identification of such disease-related genes may contribute to early detection and prevention of endometrial cancer.

KW - DNA hypermethylation

KW - DNA mismatch repair

KW - endometrial cancer

KW - epimutation

KW - HDAC inhibitor

KW - hMLH1

KW - lower uterine segment

KW - Lynch syndrome

KW - miRNA

KW - MMR

UR - http://www.scopus.com/inward/record.url?scp=84859203367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859203367&partnerID=8YFLogxK

U2 - 10.2217/epi.12.13

DO - 10.2217/epi.12.13

M3 - Article

VL - 4

SP - 147

EP - 162

JO - Epigenomics

JF - Epigenomics

SN - 1750-1911

IS - 2

ER -